Acalabrutinib

BreastfeedingPediatric
  • TRADE NAME: Calquence (AstraZeneca)
  • INDICATIONS: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
  • CLASS: Bruton’s tyrosine kinase (BTK) inhibitor
  • HALF-LIFE: <3 hours

FDA APPROVAL DATE: 10/31/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antacids, Famotidine, H2-receptor antagonists, Itraconazole, Proton pump inhibitors, Ranitidine, Rifampin, Strong CYP3A inducers, Strong or moderate CYP3A inhibitors

PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies

Our database has 30 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
OTHER


Page last updated 11/30/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric